Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.49 |
| ▸ | PPARA | Q07869 | 15/20 | 0.49 |
| ▸ | PPARD | Q03181 | 14/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4615058 | 0.99 | PPARG (0.48) | PPARGPPARAPPARDTAS1R3TAS1R1 | |
| SCHEMBL5412324 | 0.85 | PPARG (0.46) | PPARGPPARAPPARDTAS1R3TAS1R1 | |
| SCHEMBL4635056 | 0.83 | PPARG (0.55) | PPARGPPARAPPARDTAS1R3TAS1R1 | |
| SCHEMBL4615055 | 0.80 | PPARG (0.46) | PPARGPPARAPPARD | |
| SCHEMBL4614623 | 0.80 | PPARG (0.46) | PPARGPPARAPPARD | |
| SCHEMBL4616574 | 0.79 | PPARG (0.61) | PPARGPPARAPPARDALDH1A1LMNA | |
| SCHEMBL4614609 | 0.77 | PPARG (0.58) | PPARGPPARAPPARDSMN1; SMN2 | |
| SCHEMBL4615912 | 0.76 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL4615804 | 0.75 | PPARA (0.72) | PPARGPPARAPPARD | |
| SCHEMBL4614905 | 0.70 | PPARA (0.73) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697304-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
| EP-1697304-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.